The Eli Lilly-backed immuno-oncology product developer floated at the top of its range, with Bluebird Bio investing $10m.

Immunotherapy developer Sutro Biopharma has floated on the Nasdaq Global Market, providing exits for Merck & Co, Celgene, Amgen and Eli Lilly.

The lending platform's existing shareholders, which include Rocket Internet, sold $184m in shares as part of the offering.

The underwriters for the initial public offering have bought another $27m in shares in the Alphabet and Salesforce-backed online survey platform developer.

Sutro Biopharma, an immunotherapy developer commercialising technology created at Stanford University, has floated on the Nasdaq Global Market.

The home IoT platform floated at the foot of its range to raise almost $103m, while Xiaomi will retain a 16.4% stake in the company.

The Astra Zeneca antibiotic development spin off has floated in an initial public offering in which Novo bought more than $16m in shares.

Alexion will pay $400m upfront for Baxalta-backed Syntimmune, with up to an additional $800m on offer if the autoimmune disease drug developer hits all its milestones.

Grubhub agreed to acquire student-focused food delivery app Tapingo, which had raised $36m from investors including Qualcomm Ventures.

The online survey platform, which counted Alphabet and Salesforce as investors, floated above its range while increasing the number of shares in the IPO.